Vividion Therapeutics, Inc., a clinical-stage biopharmaceutical company known for its advanced discovery technologies targeting traditionally undruggable diseases with precision therapeutics, has announced plans to enhance its global innovation efforts with a new research and development (R&D) center and corporate headquarters in San Diego, California. Vividion operates as a wholly owned subsidiary of Bayer AG.
The new facility will significantly bolster Vividion’s R&D capabilities, particularly expanding its chemoproteomics screening capacity. A substantial portion of the new space will be dedicated to cutting-edge research laboratories, where the company will advance its clinical and preclinical programs, as well as future initiatives stemming from its ongoing discovery work. This expansion aims to support strategic growth and attract top-tier life sciences talent in San Diego, a burgeoning biotech hub.
“Vividion is entering a pivotal phase of growth, with numerous programs in clinical trials, a robust discovery portfolio, and a comprehensive platform screening approach aimed at addressing previously undruggable targets with small molecule therapeutics,” said Aleksandra Rizo, M.D., Ph.D., Chief Executive Officer of Vividion. “Our new R&D center and headquarters will provide the infrastructure needed to realize our strategic vision and continue leading in chemoproteomics and covalent chemistry to develop innovative medicines for patients.”
Stefan Oelrich, Member of the Board of Management at Bayer AG and President of Pharmaceuticals, added, “Vividion is a crucial part of Bayer’s innovation strategy, focused on delivering first-in-class medicines to meet unmet medical needs. This new facility will enhance our ability to leverage Vividion’s pioneering chemoproteomics platform for drug discovery and development.”
Bayer’s commitment to scientific innovation includes expanding its R&D capabilities and reinforcing its presence in key U.S. life science hubs, such as Boston, San Francisco, and Research Triangle Park, North Carolina. San Diego’s renowned biotech ecosystem, with its numerous life science companies and research institutes, presents an ideal environment for Bayer to enhance its leadership and innovation pipeline.
